Drug Profile
Research programme: ovarian reserve modulation - PregLem
Alternative Names: PGL-1001; PGL1Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Ipsen
- Developer PregLem
- Class
- Mechanism of Action Follicle stimulating hormone modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Female infertility
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Female-infertility in Switzerland
- 22 Mar 2011 Preclinical development is ongoing in Switzerland
- 07 Oct 2010 PregLem has been acquired by Gedeon Richter